-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VgXIkIVMOCkv4rz3hGHy56xw3v+0wrJame1IEQAyOpGd2U2uvA411X2Z3Kj0Qogq TRnvBrBnrV0vG+EoPrz10Q== 0000910680-07-000400.txt : 20070510 0000910680-07-000400.hdr.sgml : 20070510 20070510214817 ACCESSION NUMBER: 0000910680-07-000400 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070510 FILED AS OF DATE: 20070510 DATE AS OF CHANGE: 20070510 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Biodel Inc CENTRAL INDEX KEY: 0001322505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: 6 CHRISTOPHER COLUMBUS AVE CITY: DANBURY STATE: CT ZIP: 06810 BUSINESS PHONE: 203-798-3603 MAIL ADDRESS: STREET 1: 6 CHRISTOPHER COLUMBUS AVE CITY: DANBURY STATE: CT ZIP: 06810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ORBIMED ADVISORS LLC CENTRAL INDEX KEY: 0001055951 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33451 FILM NUMBER: 07839848 BUSINESS ADDRESS: STREET 1: 767 3RD AVENUE STREET 2: 30TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2126845700 MAIL ADDRESS: STREET 1: 767 3RD AVENUE STREET 2: 30TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 3 1 f3052007orbimedadvisors_ex.xml FORM 3 X0202 3 2007-05-10 0 0001322505 Biodel Inc BIOD 0001055951 ORBIMED ADVISORS LLC 767 THIRD AVENUE NEW YORK NY 10017 0 0 1 0 Common Stock 708136 I See Footnote Director's Stock Option (right to buy) 5.65 2014-07-10 Common Stock 17713 I See Footnote Director's Stock Option (right to buy) 12.63 2014-11-30 Common Stock 2601 I See Footnote Director Stock Option (right to buy) 15.00 2007-05-10 2017-05-09 Common Stock 25000 I See Footnote Series B Convertible Preferred Stock Common Stock 1258756 I See footnote The amount shown represents (i) 472,611 shares of Common Stock held directly by Caduceus Private Investments II LP, (ii) 176,963 shares of Common Stock held by Caduceus Private Investments II (QP), LP, and (iii) 58,562 shares of Common Stock held directly by UBS Juniper Crossover Fund, L.L.C., affiliates of the Reporting Person. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein. This option is exercisable in two equal installments on July 11, 2007 and July 11, 2008. The amount shown represents (i) options to purchase 11,822 shares of common stock, held directly by Caduceus Private Investments II LP, (ii) option to purchase 4,426 shares of common stock, held directly by Caduceus Private Investments II (QP), LP and (iii) option to purchase 1,465 shares of common stock, held directly by UBS Juniper Crossover Fund, LLC. The options were granted to Samuel Wertheimer, a director of the Issuer. Mr. Wertheimer is a principal of the Reporting Person. Mr. Wertheimer is obligated to transfer any shares issued under the options to the Reporting Person. The option is exercisable in two equal installments on December 1, 2007 and December 1, 2008. The amount shown represents (i) options to purchase 1,736 shares of common stock, held directly by Caduceus Private Investments II LP, (ii) option to purchase 650 shares of common stock, held directly by Caduceus Private Investments II (QP), LP and (iii) option to purchase 215 shares of common stock, held directly by UBS Juniper Crossover Fund, LLC. The amount shown represents (i) options to purchase 16,685 shares of common stock, held directly by Caduceus Private Investments II LP, (ii) option to purchase 6,247 shares of common stock, held directly by Caduceus Private Investments II (QP), LP and (iii) option to purchase 2,068 shares of common stock, held directly by UBS Juniper Crossover Fund, LLC. The Series B Preferred Stock has no expiration date. It is immediately convertible and will automatically convert into Common Stock of the Issuer upon the close of the Issuer's initial public offering. The amount shown represents (i) 840,081 shares of Series B Convertible Preferred Stock held directly by Caduceus Private Investments II LP, (ii) 314,543 shares of our Series B Convertible Preferred Stock held directly by Caduceus Private Investments II (QP), LP, and (iii) 104,132 shares of Series B Convertible Preferred Stock held directly by UBS Juniper Crossover Fund, L.L.C., affiliates of the Reporting Person. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein. /s/ OrbiMed Advisors 2007-05-10 -----END PRIVACY-ENHANCED MESSAGE-----